Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Ascentage Pharma Group International ( (HK:6855) ) is now available.
Ascentage Pharma Group International announced the purchase of 50,000 shares by the Trustee for the 2022 RSU Scheme, representing approximately 0.014% of the total issued shares. This move is part of the company’s ongoing efforts to satisfy the RSUs upon exercise, reflecting its commitment to employee incentives and aligning with its strategic goals.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing therapies for cancer, hepatitis B, and age-related diseases. The company is listed on the Hong Kong Stock Exchange and is involved in the research and development of novel small-molecule drugs.
YTD Price Performance: -25.96%
Average Trading Volume: 4,105,598
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$15.68B
Find detailed analytics on 6855 stock on TipRanks’ Stock Analysis page.